Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
David J. Greenblatt, Karthik Venkatakrishnan, Jerold S. Harmatz, Sarah J. Parent & Lisa L. von Moltke. (2010) Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro. Xenobiotica 40:10, pages 713-720.
Read now
Read now
Articles from other publishers (37)
Paresh P. Chothe, Sean Xiaochun Zhu, Sandeepraj Pusalkar, Chuang Lu & Cindy Xia. 2023. Oral Bioavailability and Drug Delivery. Oral Bioavailability and Drug Delivery
757
778
.
Toshinori Hirai, Shun Ueda, Toru Ogura, Kan Katayama, Kaoru Dohi, Keiko Hosohata, Takahiko Aoyama, Yoshiaki Matsumoto & Takuya Iwamoto. (2023) Hyperkalemia by eplerenone or esaxerenone in the presence or absence of clarithromycin in hypertensive patients: a retrospective observational cohort study. Journal of Hypertension 41:4, pages 580-586.
Crossref
Crossref
Ebru Arioglu-Inan & Gizem Kayki-Mutlu. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
634
655
.
Elaine Tseng, Heather Eng, Jian Lin, Matthew A. Cerny, David A. Tess, Theunis C. Goosen & R. Scott Obach. (2021) Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes. Drug Metabolism and Disposition 49:10, pages 947-960.
Crossref
Crossref
Ezequiel Cordova, Franco Garibaldi, Leandro Bono & Claudia Rodriguez. (2021) Severe hyperkalaemia due to a potential drug–drug interaction between eplerenone and antiretrovirals in a HIV-positive patient after a myocardial infarction. International Journal of STD & AIDS 32:8, pages 771-773.
Crossref
Crossref
Heather Eng, Elaine Tseng, Matthew A. Cerny, Theunis C. Goosen & R. Scott Obach. (2021) Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants. Drug Metabolism and Disposition 49:6, pages 442-450.
Crossref
Crossref
Yoshiaki Kirigaya, Masanari Shiramoto, Tomoko Ishizuka, Hinako Uchimaru, Shin Irie, Manabu Kato, Takako Shimizu, Takafumi Nakatsu, Yasuhiro Nishikawa & Hitoshi Ishizuka. (2020) Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects. British Journal of Clinical Pharmacology 86:10, pages 2070-2079.
Crossref
Crossref
Makiko Yamada, Jeanne Mendell, Hideo Takakusa, Takako Shimizu & Osamu Ando. (2019)
Pharmacokinetics, Metabolism, and Excretion of [
14
C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
. Drug Metabolism and Disposition 47:3, pages 340-349.
Crossref
Crossref
Hayato Akimoto, Akio Negishi, Shinji Oshima, Mitsuyoshi Okita, Sachihiko Numajiri, Naoko Inoue, Shigeru Ohshima & Daisuke Kobayashi. (2018)
Onset timing of statin‐induced musculoskeletal adverse events and concomitant drug‐associated shift in onset timing of
MAE
s
. Pharmacology Research & Perspectives 6:6.
Crossref
Crossref
Samet Özdemir, Burak Çelik, Engin Sümer, Ebru Türköz Acar & Melike Üner. (2018) Eplerenone nanoemulsions for treatment of hypertension. Part II: Physical stability assessment and in vivo study. Journal of Drug Delivery Science and Technology 45, pages 287-295.
Crossref
Crossref
Viljami Jokinen, Tuomas Lilius, Jouko Laitila, Mikko Niemi, Oleg Kambur, Eija Kalso & Pekka Rauhala. (2016) Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine. Basic & Clinical Pharmacology & Toxicology 120:1, pages 38-45.
Crossref
Crossref
Yoko Mano, Yuichi Sugiyama & Kiyomi Ito. (2015) Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug–Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates. Journal of Pharmaceutical Sciences 104:9, pages 3183-3193.
Crossref
Crossref
Domenic A. Sica. (2014) Aldosterone and Volume Management in Hypertensive Heart Disease. Seminars in Nephrology 34:3, pages 323-332.
Crossref
Crossref
Kiyoo Mori, Yosihide Uno, Mikiya Usukura, Kotaro Oe, Mitsuhiro Kometani, Tetsuo Konno, Kenji Sakata, Katsuharu Uchiyama, Kenshi Hayashi, Masa-aki Kawashiri & Masakazu Yamagishi. (2012) Polymorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and digitalis intoxication. Journal of Cardiology Cases 6:6, pages e166-e169.
Crossref
Crossref
Yasushi Fujioka, Kent L. Kunze & Nina Isoherranen. (2012) Risk Assessment of Mechanism-Based Inactivation in Drug-Drug Interactions. Drug Metabolism and Disposition 40:9, pages 1653-1657.
Crossref
Crossref
Javed Butler, Justin A. Ezekowitz, Sean P. Collins, Michael M. Givertz, John R. Teerlink, Mary N. Walsh, Nancy M. Albert, Cheryl A. Westlake Canary, Peter E. Carson, Monica Colvin-Adams, James C. Fang, Adrian F. Hernandez, Ray E. Hershberger, Stuart D. Katz, Joseph G. Rogers, John A. Spertus, William G. Stevenson, Nancy K. Sweitzer, W.H. Wilson Tang, Wendy Gattis Stough & Randall C. Starling. (2012) Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure 18:4, pages 265-281.
Crossref
Crossref
Hiroshi Sugimoto, Shin-Ichi Matsumoto, Miho Tachibana, Shin-Ichi Niwa, Hideki Hirabayashi, Nobuyuki Amano & Toshiya Moriwaki. (2011) Establishment of In Vitro P-Glycoprotein Inhibition Assay and Its Exclusion Criteria to Assess the Risk Of Drug–Drug Interaction at the Drug Discovery Stage. Journal of Pharmaceutical Sciences 100:9, pages 4013-4023.
Crossref
Crossref
Cindy Q. Xia, Chuang Lu & Suresh K. Balani. 2011. Oral Bioavailability. Oral Bioavailability
475
491
.
Jian Yin, Qin Meng & Xiaomei Dong. (2011) Auto-inhibition of verapamil metabolism in rat hepatocytes of gel entrapment culture. Biomedicine & Pharmacotherapy 65:5, pages 328-333.
Crossref
Crossref
Mark Jean Gnoth, Ulf Buetehorn, Uwe Muenster, Thomas Schwarz & Steffen Sandmann. (2011) In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban. Journal of Pharmacology and Experimental Therapeutics 338:1, pages 372-380.
Crossref
Crossref
Maya GuglinOlga Kristof-Kuteyeva, Irina Novotorova & Pravin Pratap. (2010) Aldosterone Antagonists in Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics 16:2, pages 150-159.
Crossref
Crossref
Mohammad Abuannadi & James H. O'Keefe. (2010) Review Article: Eplerenone: An Underused Medication?. Journal of Cardiovascular Pharmacology and Therapeutics 15:4, pages 318-325.
Crossref
Crossref
Judy W.M. Cheng, William H. Frishman & Wilbert S. Aronow. (2010) Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions. Disease-a-Month 56:3, pages 163-179.
Crossref
Crossref
Chuang Lu, Suresh K. Balani, Mark G. Qian, Shimoga R. Prakash, Patricia S. Ducray & Lisa L. von Moltke. (2010) Quantitative Prediction and Clinical Observation of a CYP3A Inhibitor-Based Drug-Drug Interactions with MLN3897, a Potent C-C Chemokine Receptor-1 Antagonist. Journal of Pharmacology and Experimental Therapeutics 332:2, pages 562-568.
Crossref
Crossref
Akihiro Hisaka, Yoshiyuki Ohno, Takehito Yamamoto & Hiroshi Suzuki. (2010) Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacology & Therapeutics 125:2, pages 230-248.
Crossref
Crossref
Albert P. Li & Chuang Lu. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
423
441
.
Judy W M Cheng, William H Frishman & Wilbert S Aronow. (2009) Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions. American Journal of Therapeutics 16:2, pages 155-163.
Crossref
Crossref
Olavi Pelkonen, Miia Turpeinen, Jukka Hakkola, Paavo Honkakoski, Janne Hukkanen & Hannu Raunio. (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Archives of Toxicology 82:10, pages 667-715.
Crossref
Crossref
Chuang Lu, Panos Hatsis, Cicely Berg, Frank W. Lee & Suresh K. Balani. (2008) Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. II. In Vitro-in Vivo Correlation with Ketoconazole. Drug Metabolism and Disposition 36:7, pages 1255-1260.
Crossref
Crossref
Qing Huang, Guang‐Ji Wang, Jian‐Guo Sun, Xiao‐Lin Hu, Yi‐Hong Lu & Qian Zhang. (2007) Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry 21:6, pages 1009-1018.
Crossref
Crossref
Chuang Lu, Gerald T. Miwa, Shimoga R. Prakash, Liang-Shang Gan & Suresh K. Balani. (2007) A Novel Model for the Prediction of Drug-Drug Interactions in Humans Based on in Vitro Cytochrome P450 Phenotypic Data. Drug Metabolism and Disposition 35:1, pages 79-85.
Crossref
Crossref
T. Rau & T. Eschenhagen. (2007) Aldosteron und Aldosteronrezeptorantagonisten in der HerzinsuffizienztherapieAldosterone and aldosterone receptor antagonists in the therapy of cardiac failure. Clinical Research in Cardiology Supplements 2:1, pages 55-64.
Crossref
Crossref
Domenic A. Sica. (2005) The risks and benefits of aldosterone antagonists. Current Heart Failure Reports 2:2, pages 65-71.
Crossref
Crossref
A. S. Mihailidou. (2005) Nongenomic Cardiovascular Actions of Aldosterone: A Receptor for All Seasons?. Endocrinology 146:3, pages 971-972.
Crossref
Crossref
Luis Michea, Ana M. Delpiano, Catalina Hitschfeld, Lorena Lobos, Sergio Lavandero & Elisa T. Marusic. (2005) Eplerenone Blocks Nongenomic Effects of Aldosterone on the Na+/H+ Exchanger, Intracellular Ca2+ Levels, and Vasoconstriction in Mesenteric Resistance Vessels. Endocrinology 146:3, pages 973-980.
Crossref
Crossref
Michiharu Kageyama, Hitomi Namiki, Hiroto Fukushima, Yukako Ito, Nobuhito Shibata & Kanji Takada. (2005) In Vivo Effects of Cyclosporin A and Ketoconazole on the Pharmacokinetics of Representative Substrates for P-Glycoprotein and Cytochrome P450 (CYP) 3A in Rats. Biological and Pharmaceutical Bulletin 28:2, pages 316-322.
Crossref
Crossref
Domenic A. Sica. (2005) Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis. Heart Failure Reviews 10:1, pages 23-29.
Crossref
Crossref